Prolintane: Difference between revisions

Line 6:

| ''[[Prolintane/Summary|Summary sheet: Prolintane]]''

|}

'''1-Phenyl-2-pyrrolidinylpentane''' (also known as '''Prolintane''', '''Pyrrolidinopentiophenone''', and by the trade names '''Catovit''', '''Promotil''', and '''Villescon''') is a synthetic central nervous system (CNS) [[psychoactive class::stimulant]] compound that is a functional analog of [[amphetamine]] and structurally analogous to [[substituted pyrovalerone|pyrovalerone]]-related compounds such as [[MDPV]] and [[A-PVP]]. Prolintane was first synthesized in the 1950s, where it was found primarily to act as as a [[norepinephrine]]-[[dopamine]] [[reuptake inhibitor]] (NDRI)<ref>GB Patent 807835</ref> which is thought to confer it [[stimulant]] and potential [[nootropic]] qualities.

'''1-Phenyl-2-pyrrolidinylpentane''' (also known as '''Prolintane''' or '''Pyrrolidinopentiophenone''', and by the trade names '''Catovit''', '''Promotil''', and '''Villescon''') is a synthetic central nervous system (CNS) [[psychoactive class::stimulant]] compound that is a functional analog of [[amphetamine]] and structurally analogous to [[substituted pyrovalerone|pyrovalerone]]-related compounds such as [[MDPV]] and [[A-PVP]]. Prolintane was first synthesized in the 1950s, where it was found primarily to act as as a [[norepinephrine]]-[[dopamine]] [[reuptake inhibitor]] (NDRI)<ref>GB Patent 807835</ref> which is thought to confer it [[stimulant]] and potential [[nootropic]] qualities.

Historical reports show records of the preparation of prolintane for use as a mild CNS stimulant, wakefulness agent, and [[cocaine]]-cessation aid. It has been marketed in Europe since the 1960s as an antidepressant (i.e. antifatigue properties) and analeptic. It has a history of being used in neuropsychiatric research related to CNS stimulants with reduced side effects. Therapeutic uses of prolintane in Africa, Europe, and Australia include the treatment of narcolepsy, ADHD, fatigue and orthostatic hypotension. It is not approved for pharmaceutic use in the United States.<ref>Barceloux, D. G. (2012). Medical toxicology of drug abuse: synthesized chemicals and psychoactive plants (pp. 69-70). Wiley.</ref>

@@ Line 6: / Line 6: @@
 | ''[[Prolintane/Summary|Summary sheet: Prolintane]]''
 |}
-'''1-Phenyl-2-pyrrolidinylpentane''' (also known as '''Prolintane''', '''Pyrrolidinopentiophenone''', and by the trade names '''Catovit''', '''Promotil''', and '''Villescon''') is a synthetic central nervous system (CNS) [[psychoactive class::stimulant]] compound that is a functional analog of [[amphetamine]] and structurally analogous to [[substituted pyrovalerone|pyrovalerone]]-related compounds such as [[MDPV]] and [[A-PVP]]. Prolintane was first synthesized in the 1950s, where it was found primarily to act as as a [[norepinephrine]]-[[dopamine]] [[reuptake inhibitor]] (NDRI)<ref>GB Patent 807835</ref> which is thought to confer it [[stimulant]] and potential [[nootropic]] qualities.
+'''1-Phenyl-2-pyrrolidinylpentane''' (also known as '''Prolintane''' or '''Pyrrolidinopentiophenone''', and by the trade names '''Catovit''', '''Promotil''', and '''Villescon''') is a synthetic central nervous system (CNS) [[psychoactive class::stimulant]] compound that is a functional analog of [[amphetamine]] and structurally analogous to [[substituted pyrovalerone|pyrovalerone]]-related compounds such as [[MDPV]] and [[A-PVP]]. Prolintane was first synthesized in the 1950s, where it was found primarily to act as as a [[norepinephrine]]-[[dopamine]] [[reuptake inhibitor]] (NDRI)<ref>GB Patent 807835</ref> which is thought to confer it [[stimulant]] and potential [[nootropic]] qualities.
 Historical reports show records of the preparation of prolintane for use as a mild CNS stimulant, wakefulness agent, and [[cocaine]]-cessation aid. It has been marketed in Europe since the 1960s as an antidepressant (i.e. antifatigue properties) and analeptic. It has a history of being used in neuropsychiatric research related to CNS stimulants with reduced side effects. Therapeutic uses of prolintane in Africa, Europe, and Australia include the treatment of narcolepsy, ADHD, fatigue and orthostatic hypotension. It is not approved for pharmaceutic use in the United States.<ref>Barceloux, D. G. (2012). Medical toxicology of drug abuse: synthesized chemicals and psychoactive plants (pp. 69-70). Wiley.</ref>